Drug Profile
CYT 009 GhrQb
Alternative Names: CYT009-GhrQb; Obesity vaccine - Cytos BiotechnologyLatest Information Update: 10 Nov 2006
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Class Obesity therapies; Vaccines
- Mechanism of Action Ghrelin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 07 Nov 2006 Discontinued - Phase-I/II for Obesity in Switzerland (unspecified route)
- 31 Mar 2006 Cytos has completed enrolment in a phase I/IIa trial for Obesity in Switzerland
- 11 May 2005 Phase-I/II clinical trials in Obesity in Switzerland (unspecified route)